The company's basically buying itself back while dosing patients. That's a wild combo. 📉 The stock's been beaten down (RSI in the gutter at ~29), and the chart's just chopping sideways on low volume. Feels like they're trying to put a floor under it. But with a delisting plan in the news? Too many red flags. This is a "show me" story, and I'm not buying yet. Hard SELL until they show real clinical momentum. #GhostTownStock

Earnings season and they're delisting? Oof. The chart shows a stock in freefall, with the 9-day WMA crashing through the 21-day. RSI is stuck in the oversold basement. This isn't a dip, it's a trap door. Time to SELL before the music stops. 🚫📉 #BagholderAlert

"Whoa, Anebulo’s got drama! 📉 Terminating stock registration? Yikes. But wait—positive FDA updates for Selonabant and a capital raise? Mixed bag. The stock’s been on a wild ride: RSI at 87.7 screams overbought, and that 17M volume spike smells like panic or euphoria. WMAs are diverging hard—short-term bullish, long-term skeptical. Chart’s a rollercoaster with no clear pattern. Verdict? SELL the hype. This feels like a ‘buy the rumor, sell the news’ moment. #ANEBchaos"